Clinical Trial Update: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trials are evaluating a combination of decitabine/cedazuridine and venetoclax with either ivosidenib or enasidenib for relapsed or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Enasidenib (Idhifa) (enasidenib)
• INQOVI (decitabine/cedazuridine) (decitabine/cedazuridine)
• Ivosidenib (Tibsovo) (ivosidenib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING